Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 37 GP13.06 | DOI: 10.1530/endoabs.37.GP.13.06

ECE2015 Guided Posters Diabetes and obesity – Translational cardiovascular and obesity (8 abstracts)

Effects of testosterone replacement therapy on lean body mass, total fat mass, and insulin sensitivity in aging men with type 2 diabetes - a randomised, double-blinded, placebo-controlled trial

Line Velling Magnussen 1 , Dorte Glintborg 1 , Pernille Hermann 1 , David M Hougaard 2 , Kurt Højlund 1 & Marianne S Andersen 1

104 views


1Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark; 2Department of Clinical Biochemistry and Immunology, Statens Serum Institute, Copenhagen, Denmark.


Lowered testosterone levels may be observed in up to 50% of ageing men with type 2 diabetes (T2D). Testosterone replacement therapy (TRT) increases lean body mass in men with lowered testosterone levels and T2D, but the effect of TRT on glucose metabolism has not been evaluated by euglycemic hyperinsulinemic clamp.

We used gold standard methods to evaluate the effect of TRT on body composition, insulin sensitivity, and oxidative metabolism in men with T2D and lowered bio-available testosterone. Our main objective was to determine whether TRT could be a novel treatment for T2D in ageing men with lowered bio-available testosterone.

Results: Lean body mass (b=1.9 kg, P=0.001) increased during TRT, while total fat mass (b=−1.3 kg, b=0.009) and HDL cholesterol (b=−0.11 mmol/l, P=0.009) decreased. Insulin-stimulated glucose disposal rate was unchanged during TRT compared to placebo (P=0.28). Lipid and glucose oxidation during fasting and insulin stimulation were unchanged.

Conclusions: Insulin sensitivity was unchanged in men with T2D despite significant beneficial changes in lean body mass and total fat mass after 24 weeks TRT. Furthermore, HDL cholesterol levels were reduced during TRT. Our data do not suggest testosterone replacement therapy as a novel therapy for type 2 diabetes in ageing men.

Disclosure: This study was financially supported by the Novo Nordic Foundation, Odense University Hospital, Institute of Clinical Research at the University of Southern Denmark, the Region of Southern Denmark, Consultant Council Scholarship Committee of O.

Article tools

My recent searches

No recent searches.